Aclaris Therapeutics vs Outlook Therapeutics
Aclaris Therapeutics is the larger business, with $7.8m of revenue in fiscal 2025 against $1.4m for Outlook Therapeutics (5.5 times as much). Aclaris Therapeutics grew faster (-58.2% against -82.6%). Aclaris Therapeutics kept more of each dollar of sales as profit: a net margin of -829.6% against -4416.2%.
| Latest fiscal year | Aclaris TherapeuticsACRS, 2025 | Outlook TherapeuticsOTLK, 2025 |
|---|---|---|
| Revenue | $7.8m | $1.4m |
| Revenue growth | -58.2% | -82.6% |
| Net income | −$64.9m | −$62.4m |
| Operating margin | -975.9% | — |
| Net margin | -829.6% | -4416.2% |
| Return on equity | -50.2% | — |
| Free cash flow | −$47.2m | −$51.8m |
| Cash | $20.0m | $8.1m |
| Total debt | $0 | $29.9m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | 17 |
| Market value | $515m | $86.1m |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 0 buys, 1 sales | 10 buys, 0 sales |